%0 Observational Study
%T Single-center, prospective, and observational study on the management and treatment of impetigo in a pediatric population.
%A Gatto A
%A Capossela L
%A Ferretti S
%A Di Sarno L
%A Oliveti A
%A Talamonti D
%A Curatola A
%A Chiaretti A
%A Fiori B
%J Eur Rev Med Pharmacol Sci
%V 27
%N 19
%D 2023 Oct
%M 37843341
%F 3.784
%R 10.26355/eurrev_202310_33955
%X <B>OBJECTIVE: </B>Ozenoxacin is a new antibiotic used to treat non-bullous impetigo. The aim of this study is to evaluate the microbiological and clinical efficacy of topical ozenoxacin 1% cream after 5-day twice-daily treatment, in pediatric patients with impetigo.<BR><B>METHODS: </B>This observational and prospective study included patients aged 6 months to 18 years, with non-bullous impetigo. Efficacy was measured using the Skin Infection Rating Scale (SIRS) and microbiological culture at the first visit (T0), at the second visit after 72 hours (T1) and after 5 days (T2). Safety and tolerability were also evaluated.<BR><B>RESULTS: </B>A total of 50 patients was enrolled. A reduction of SIRS score >10% after 72 hours of treatment was noticed in all patients, while a complete reduction was assessed after 5 days in all the population. Microbiologic success rates for ozenoxacin at T1 was 92% (four patients had original pathogens in the specimen culture from the skin area), whereas at T2, it was 100%.<BR><B>CONCLUSIONS: </B>Topical ozenoxacin has strong efficacy in treating impetigo in pediatric patients. Ozenoxacin's clinical and microbiological rapid onset of response led to consider this antibiotic a novel efficacy option for the treatment of impetigo.